Clinical Trials Browser

Phase 3 × BID protein, human × Other hematologic neoplasm × Clear all

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02627677 2021-11-26

OPTIC-2L

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Clinical Trials

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

OPTIC-2L